Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

Clinical trial NCT06821659 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06821659
Sponsor: Peking University Third Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Systemic Lupus Erthematosus Systemic Sclerosis (SSc)Inflammatory Myopathies ANCA Associated Vasculitis (AAV)Sjogren Syndrome

Start date: 2025-03-01
Primary completion: 2027-12-31
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.